Key statistics
On Friday, Allarity Therapeutics Inc (ALLR:NAQ) closed at 2.21, 24.16% above the 52 week low of 1.78 set on Sep 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.23 |
---|---|
High | 2.29 |
Low | 2.04 |
Bid | -- |
Offer | -- |
Previous close | 2.26 |
Average volume | 1.72m |
---|---|
Shares outstanding | 1.41m |
Free float | 1.36m |
P/E (TTM) | -- |
Market cap | 3.12m USD |
EPS (TTM) | -2,217.58 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
- Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)
- Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
- Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
- Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
- Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
- Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
- Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
- Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
More ▼